BDNF and neoplasm: Our data support the idea that BDNF/TRKB signaling may regulate tumor progression in OSCC, especially PD-OSCC, and that high expression of these molecules may be an attractive prognostic marker for tumor aggressiveness, as well as a potential target for OSCC therapies.